Wang and colleagues have recently demonstrated that the combination of crizotinib and an alternative CD30 antibody–drug conjugate, anti-CD30-lidamycin, were more effective than single agent therapy in both in vitro and xenograft models of ALCL.57 The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.